Chronocort Effective in Adults with Congenital Adrenal Hyperplasia

Mortality Increased Among Congenital Adrenal Hyperplasia Patients
Mortality Increased Among Congenital Adrenal Hyperplasia Patients
Chronocort was effective in treating congenital adrenal hyperplasia in a phase 2 trial.

Context: Treatment of congenital adrenal hyperplasia (CAH) is suboptimal. Inadequate suppression of androgens and glucocorticoid excess are common and current glucocorticoid formulations cannot replace the cortisol circadian rhythm.

Objectives: The primary objective was to characterize the pharmacokinetic profile of Chronocort®, a modified-release hydrocortisone formulation, in adults with CAH. Secondary objectives included examining disease control following 6 months of Chronocort® with dose titration.

Conclusions: Twice daily Chronocort® approximates physiologic cortisol secretion, and was well tolerated and effective in controlling androgen excess in adults with CAH. This novel hydrocortisone formulation represents a new treatment approach for patients with CAH.

READ FULL ARTICLE Curated publisher From